More tools:Markets·Screener·Research·Chat

Lineage Cell Therapeutics, Inc. (LCTX) Financial Statements

Lineage Cell Therapeutics, Inc.
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SCW8V3
XASE · usd
1.03▼ 0.06 (-5.50%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close1.09
Day's Range1.03 – 1.12
52-Week Range1.00 – 2.09
Volume1.3M
Avg Volume872.3K
Share Statistics
Shares Outstanding
Employees77
ExchangeXASE
Listed1992-03-05
Share count as of August 3, 2026
Loading Income Statement…
Key questions about Lineage Cell Therapeutics, Inc. (LCTX)
What is Lineage Cell Therapeutics, Inc.'s Market Cap?
Lineage Cell Therapeutics, Inc.'s Market Cap is $260.5M, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s Enterprise Value?
Lineage Cell Therapeutics, Inc.'s Enterprise Value is $209.7M, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s Price / Sales?
Lineage Cell Therapeutics, Inc.'s Price / Sales is 19.9×, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s EV / Revenue?
Lineage Cell Therapeutics, Inc.'s EV / Revenue is 16.0×, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s EV / EBITDA?
Lineage Cell Therapeutics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s Revenue (TTM)?
Lineage Cell Therapeutics, Inc.'s Revenue (TTM) is $13.1M, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s Net Income (TTM)?
Lineage Cell Therapeutics, Inc.'s Net Income (TTM) is -$32.3M, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s EBITDA?
Lineage Cell Therapeutics, Inc.'s EBITDA is -$26.1M, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s Diluted EPS (TTM)?
Lineage Cell Therapeutics, Inc.'s Diluted EPS (TTM) is -0.13, based on as-reported figures from SEC (XBRL) filings.
What is Lineage Cell Therapeutics, Inc.'s EBITDA Margin?
Lineage Cell Therapeutics, Inc.'s EBITDA Margin is -199.6%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Total revenues
YoY growth-61.3%+14.8%+130.4%-2.6%
OPERATING EXPENSES:
Cost of royalties
Research and development
General and administrative
Loss on impairment of intangible asset (Note 6 and Note 13)—
Total operating expenses
% of revenue934.7%540.2%199.1%202.9%
Loss from operations
% of revenue-834.7%-440.2%-99.1%-102.9%
OTHER INCOME (EXPENSES):
Interest income, net
Gain (loss) on marketable equity securities, net
Change in fair value of warrant liability
Other income (expense), net
Total other income (expenses)
NET LOSS—
NET INCOME (LOSS)———
% of revenue144.4%———
Net (income) loss attributable to noncontrolling interest
NET INCOME (LOSS) ATTRIBUTABLE TO LINEAGE
% of revenue138.6%-279.0%12.9%-809.0%
NET INCOME (LOSS) PER COMMON SHARE ATTRIBUTABLE TO LINEAGE:
Basic
Diluted